# Cumberland Pharmaceuticals (CPIX) — News

CPIX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cpix/news

## Recent headlines

- [CPBIO renewal of continuing connected transactions, notice of special general meeting](https://www.ainvest.com/news/cpbio-renewal-continuing-connected-transactions-notice-special-general-meeting-2610-19) — AInvest Wire, Oct 13, 2026
  Cancer Prevention & Biotechnology Limited (CPBIO) has announced the renewal of its continuing connected transactions, as disclosed in a recent regulatory filing. The company has also issued a notice of a special general meeting (SGM) to be held on October 30, 2026, for shareholders to consider and…
- [CPBIO renewal of continuing connected transactions, notice of special general meeting](https://www.ainvest.com/news/cpbio-renewal-continuing-connected-transactions-notice-special-general-meeting-2610) — AInvest Wire, Oct 13, 2026
- [Cumberland: Conv pref to have initial stated value of $10K/shr](https://www.ainvest.com/news/cumberland-conv-pref-initial-stated-10k-shr-2609) — AInvest Wire, Sep 4, 2026
  Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) has announced that its newly issued convertible preferred shares will carry an initial stated value of $10,000 per share. This decision aligns with the company’s broader capital-raising strategy and reflects the accounting and classification…
- [Cumberland Pharmaceuticals Q2 adjusted EPS USD -0.2](https://www.ainvest.com/news/cumberland-pharmaceuticals-q2-adjusted-eps-usd-0-2-2608) — AInvest Wire, Aug 4, 2026
  Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported an adjusted earnings loss of $0.20 per diluted share for the second quarter of 2026, according to its recent financial results. This represents a decline compared to adjusted earnings of $0.18 per diluted share in the same period in 2025. The…
- [Cumberland Pharmaceuticals - authorizes open-market share repurchase program of up to $5 mln](https://www.ainvest.com/news/cumberland-pharmaceuticals-authorizes-open-market-share-repurchase-program-5-mln-2607) — AInvest Wire, Jul 13, 2026
  Cumberland Pharmaceuticals Inc. has announced the authorization of an open-market share repurchase program, with a maximum value of $5 million . The program, which is subject to market conditions and other factors, allows the company to repurchase shares of its common stock in compliance with…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).